Literature DB >> 20648474

I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.

Luca Valenti1, Anna Alisi, Enrico Galmozzi, Andrea Bartuli, Benedetta Del Menico, Arianna Alterio, Paola Dongiovanni, Silvia Fargion, Valerio Nobili.   

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in children. Genetic variability, which is a main player in NAFLD, is especially characterized by polymorphisms in genes involved in the development and progression of the disease to nonalcoholic steatohepatitis (NASH). Recently, the rs738409 C>G adiponutrin/patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism, which encodes the I148M protein variant in the catalytic domain, has been associated with severe steatosis, NASH, and liver fibrosis in adults. In this study, we investigated the association between the rs738409 PNPLA3 gene polymorphism and NAFLD in 149 consecutive children and adolescents (age = 6-13 years) with biopsy-proven NAFLD. We analyzed the rs738409 polymorphism by a 5'-nuclease TaqMan assay and assessed its association with NASH: 41% of the subjects with NAFLD showed heterozygosity and 15% showed homozygosity for the at-risk G allele. The rs738409 genotype did not influence the body mass, adiposity, lipid levels, or insulin resistance and was not associated with alanine aminotransferase levels. Interestingly, the rs738409 G allele was strongly associated with the severity of steatosis (P < 0.0001), the presence of NASH (P < 0.0001), hepatocellular ballooning (P < 0.0001), lobular inflammation (P < 0.0001), and the presence of fibrosis (P = 0.01) independently of confounders. Individuals carrying two minor G alleles almost always had severe steatosis and NASH, heterozygotes were at intermediate risk, and patients negative for G alleles had milder and often uncomplicated steatosis.
CONCLUSION: The PNPLA3 rs738409 polymorphism is associated with steatosis severity, hepatocellular ballooning, lobular inflammation, and perivenular fibrosis in pediatric NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20648474     DOI: 10.1002/hep.23823

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  95 in total

1.  Understanding the role of PNPLA3 genetic variants in patients with chronic hepatitis C infection.

Authors:  Alessio Aghemo
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

Review 2.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

4.  Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study.

Authors:  Lynne E Wagenknecht; Nicholette D Palmer; Donald W Bowden; Jerome I Rotter; Jill M Norris; Julie Ziegler; Yii-Der I Chen; Steven Haffner; Ann Scherzinger; Carl D Langefeld
Journal:  Liver Int       Date:  2011-01-13       Impact factor: 5.828

5.  Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey D Browning; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 6.  Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling.

Authors:  Rosalind A Coleman; Douglas G Mashek
Journal:  Chem Rev       Date:  2011-06-01       Impact factor: 60.622

Review 7.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

Review 8.  Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management.

Authors:  Stavra A Xanthakos; Rohit Kohli
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

9.  Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Authors:  Elina Isokuortti; You Zhou; Markku Peltonen; Elisabetta Bugianesi; Karine Clement; Dominique Bonnefont-Rousselot; Jean-Marc Lacorte; Amalia Gastaldelli; Detlef Schuppan; Jörn M Schattenberg; Antti Hakkarainen; Nina Lundbom; Pekka Jousilahti; Satu Männistö; Sirkka Keinänen-Kiukaanniemi; Juha Saltevo; Quentin M Anstee; Hannele Yki-Järvinen
Journal:  Diabetologia       Date:  2017-06-29       Impact factor: 10.122

10.  PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.